As the Vice President and Head of Clinical Development at Cognition Therapeutics, Inc., Paul Tiseo plays a pivotal role in advancing innovative therapeutic solutions for age-related neurodegenerative diseases, particularly Alzheimer's Disease and Lewy Body Dementia. With a robust background in CNS drug development, Paul is...
As the Vice President and Head of Clinical Development at Cognition Therapeutics, Inc., Paul Tiseo plays a pivotal role in advancing innovative therapeutic solutions for age-related neurodegenerative diseases, particularly Alzheimer's Disease and Lewy Body Dementia. With a robust background in CNS drug development, Paul is adept at navigating the complexities of clinical program leadership, ensuring that each initiative adheres to the highest standards of quality, safety, and ethical considerations. His resourceful and forward-thinking approach has been instrumental in guiding high-value clinical development programs through their entire lifecycle, from the initial creation of clinical strategies to the execution of early-phase trials.
At Cognition Therapeutics, Paul is accountable for the cross-functional development and execution of clinical strategies that drive the company's mission to discover and develop small molecule therapeutics targeting critical areas of unmet medical need. His expertise in medical monitoring and KOL management is complemented by his proficiency in budget development and commercialization strategies, enabling him to effectively align clinical objectives with broader business goals. Paul’s leadership extends to fostering collaboration among clinical teams, ensuring that all stakeholders are engaged and informed throughout the process. His commitment to advancing neuroscience research is reflected in his ability to translate complex scientific concepts into actionable clinical plans, ultimately contributing to the successful launch of innovative therapies that can significantly improve patient outcomes in the realm of neurodegenerative diseases.
